Late‐onset Pneumocystis jirovecii pneumonia post–fludarabine, cyclophosphamide and rituximab: implications for prophylaxis

OBJECTIVE: Fludarabine, cyclophosphamide and rituximab (FCR) therapy for lymphoid malignancies has historically been associated with a low reported incidence of Pneumocystis jirovecii pneumonia (PJP). However, prophylaxis was routinely used in early studies, and molecular diagnostic tools were not e...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur J Haematol
Autors principals: Haeusler, Gabrielle M., Slavin, Monica A., Seymour, John F., Lingaratnam, Senthil, Teh, Benjamin W., Tam, Constantine S., Thursky, Karin A., Worth, Leon J.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2013
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7163499/
https://ncbi.nlm.nih.gov/pubmed/23668894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ejh.12135
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars